NEW YORK, March 2, 2015 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced Bionomics Ltd.
(ASX: BNO; OTCQX: BNOEF), a global biopharmaceutical company
developing better treatments for cancer and central nervous system
disorders, has qualified to trade on OTCQX®, the best
marketplace for established, global and growth companies.
Logo -
http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
Bionomics begins trading today on OTCQX under the symbol
"BNOEF." U.S. investors can find current financial disclosure
and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
"We are pleased to welcome Bionomic to OTCQX," said R. Cromwell Coulson, President and CEO of OTC
Markets Group. "Trading on OTCQX will broaden Bionomics'
exposure to U.S. investors through transparent trading and broad
distribution of its news and financial disclosure in the U.S.
We look forward to supporting Bionomics and its shareholders as the
company continues to expand its presence in the U.S. market and
globally."
"We have seen growing interest from U.S. investors in Bionomics
joining the OTCQX marketplace – a logical move that will provide
new opportunities for the company," said Dr. Deborah Rathjen, Bionomics' CEO and Managing
Director.
Cowen and Company, LLC serves as Bionomics' Principal American
Liaison ("PAL") on OTCQX, responsible for providing professional
guidance on OTCQX requirements.
Bionomics discovers and develops biopharmaceuticals for the
treatment of cancer, immune diseases and disorders of the central
nervous system in Australia,
France and the United
States. Its oncology approach includes cancer stem cell
therapeutics as well as vascular disruption in solid tumors.
Bionomics' discovery and development activities are driven by
its four proprietary technology platforms: MultiCore®, a diversity
orientated chemistry platform for the discovery of small molecule
drugs; ionX® , a set of novel technologies for the identification
of drugs targeting ion channels for diseases of the central nervous
system; Angene®, a drug discovery platform which incorporates a
variety of genomics tools to identify and validate novel
angiogenesis targets (involved in the formation of new blood
vessels); and CSC Rx Discovery™, which identifies antibody and
small molecule therapeutics that inhibit the growth of cancer stem
cells. These platforms drive Bionomics' pipeline and underpin its
established business strategy of securing partners for its key
compounds. Bionomics partners include Merck & Co.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates Open, Transparent and Connected financial
marketplaces for 10,000 U.S. and global securities. Through
our OTC Link® ATS, we directly link a diverse network of
broker-dealers that provide liquidity and execution services for a
wide spectrum of securities. We organize these securities
into marketplaces to better inform investors of opportunities and
risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture
Marketplace; and OTC Pink®, The Open Marketplace. Our
data-driven platform enables investors to easily trade through the
broker of their choice at the best possible price and empowers a
broad range of companies to improve the quality and availability of
information for their investors. To learn more about how we
create better informed and more efficient financial marketplaces,
visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia
Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
saskia@otcmarkets.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-bionomics-to-otcqx-300042812.html
SOURCE OTC Markets Group Inc.